These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2653624)

  • 1. Review of clinical studies of bile acid sequestrants for lowering plasma lipid levels.
    LaRosa J
    Cardiology; 1989; 76 Suppl 1():55-61; discussion 61-4. PubMed ID: 2653624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bile acid sequestrants.
    Ast M; Frishman WH
    J Clin Pharmacol; 1990 Feb; 30(2):99-106. PubMed ID: 2179278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bile acid sequestrants and hyperlipidaemia.
    Lancet; 1988 Jan; 1(8579):220-1. PubMed ID: 2893044
    [No Abstract]   [Full Text] [Related]  

  • 4. [A comparative study of colestipol and colestyramine in children and adolescents with familial hypercholesterolaemia (author's transl)].
    Mordasini R; Twelsick F; Oster P; Schellenberg B; Raetzer H; Heuck CC; Schlierf G
    Monatsschr Kinderheilkd (1902); 1978 Jul; 126(7):436-40. PubMed ID: 672910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colestipol, clofibrate, cholestyramine and combination therapy in the treatment of familial hyperbetalipoproteinaemia.
    Stein EA; Heimann KW
    S Afr Med J; 1975 Jul; 49(31):1252-6. PubMed ID: 168650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertriglyceridemia: a relative contraindication to the use of bile acid-binding resins?
    Denke MA; Grundy SM
    Hepatology; 1988; 8(4):974-5. PubMed ID: 3391527
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of hypocholesterolemic activities of the bile acid sequestrants cholestyramine and colestipol hydrochloride in cholesterol fed SEA quail.
    Day CE
    Artery; 1990; 17(5):281-8. PubMed ID: 2396902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs.
    Brown WV
    Cardiology; 1989; 76 Suppl 1():45-51; discussion 52-4. PubMed ID: 2653623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins.
    Crouse JR
    Am J Med; 1987 Aug; 83(2):243-8. PubMed ID: 3618626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clofibrate-induced low density liporotein elevation. Therapeutic implications and treatment by colestipol resin.
    Rose HG; Haft GK; Juliano J
    Atherosclerosis; 1976; 23(3):413-27. PubMed ID: 178325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colestipol and cholestyramine resin. Comparative effects in familial type II hyperlipoproteinemia.
    Glueck CJ; Ford S; Scheel D; Steiner P
    JAMA; 1972 Nov; 222(6):676-81. PubMed ID: 4562098
    [No Abstract]   [Full Text] [Related]  

  • 12. Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia.
    Heel RC; Brogden RN; Pakes GE; Speight TM; Avery GS
    Drugs; 1980 Mar; 19(3):161-80. PubMed ID: 6988203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric familial type II hyperlipoproteinemia: therapy with diet and colestipol resin.
    Glueck CJ; Fallat RW; Mellies M; Tsang RC
    Pediatrics; 1976 Jan; 57(1):68-74. PubMed ID: 174057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, tolerance, and safety of colestipol HCL as a hypocholesterolemic agent in hyperlipidemic patients with studies of its effect on gastrointestinal absorption.
    Faruqui AM; Thurmond MS; Wenger J; Wenger NK
    J Pak Med Assoc; 1981 Nov; 31(11):241-5. PubMed ID: 6802993
    [No Abstract]   [Full Text] [Related]  

  • 15. Colestipol in familial type II hyperlipoproteinemia: a three-year trial.
    Harvengt C; Desager JP
    Clin Pharmacol Ther; 1976 Sep; 20(3):310-4. PubMed ID: 182429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis.
    Glueck CJ
    Ann Intern Med; 1982 Apr; 96(4):475-82. PubMed ID: 7039445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
    Illingworth DR; Bacon S
    Arteriosclerosis; 1989; 9(1 Suppl):I121-34. PubMed ID: 2492189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of long-term diet and diet plus bile acid-binding resin cholesterol-lowering therapy in 73 children heterozygous for familial hypercholesterolemia.
    Glueck CJ; Mellies MJ; Dine M; Perry T; Laskarzewski P
    Pediatrics; 1986 Aug; 78(2):338-48. PubMed ID: 3526270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of combined diet and colestipol in long-term (7--7 1/2 years) treatment of patients with type II hyperlipoproteinemia.
    Kuo PT; Hayase K; Kostis JB; Moreyra AE
    Circulation; 1979 Feb; 59(2):199-211. PubMed ID: 215338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bile acid sequestrants as a therapeutic option for glucose lowering in type 2 diabetes mellitus.
    Levy P
    Endocr Pract; 2008; 14(5):644-7. PubMed ID: 18753111
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.